查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012315

次世代定序市場：依技術、產品類型、工作流程、最終用戶和應用分類－2026-2032年全球市場預測

Next Generation Sequencing Market by Technology, Product Type, Workflow, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計次世代定序市場在 2025 年的價值為 266.9 億美元，在 2026 年成長至 317.7 億美元，到 2032 年達到 1257.8 億美元，複合年成長率為 24.78%。

主要市場統計數據
基準年 2025 266.9億美元
預計年份：2026年 317.7億美元
預測年份 2032 1257.8億美元
複合年成長率 (%) 24.78%

將技術進步和臨床應用與營運重點和相關人員決策連結起來的次世代定序策略方法。

次世代定序(NGS) 已從一項小眾實驗室技術發展成為塑造生物醫學研究、診斷和生物製藥創新的基礎平台。本文概述了 NGS 的技術成熟度、不斷擴展的臨床應用以及決策者為有效利用 NGS 所必須應對的營運挑戰。定序化學、儀器處理能力和生物資訊工具集的進步降低了技術門檻。同時，NGS 在腫瘤學、感染疾病監測和罕見疾病遺傳學等領域的實際臨床應用也展現出實際的臨床效用。同時，隨著定序資料在患者照護和治療方法開發中的應用日益廣泛，各機構也面臨著對資料品質、互通性和合規性日益成長的期望。

技術、分析和監管趨勢的融合正在重新定義定序能力、檢驗預期和協作部署模式。

次世代定序技術正經歷著一場變革性的轉變，多種因素共同作用，重塑其功能和應用。首先，儀器創新持續提升速度、準確性和成本效益，從而催生了新的應用場景，例如快速識別感染疾病病原體和腫瘤即時檢驗。其次，生物資訊學正從客製化腳本轉向日益標準化和驗證的流程，這些流程整合了比對、註釋和變異檢測，能夠提供適用於臨床報告的可重複結果。這些調查方法的進步降低了檢查室間的差異，縮短了結果獲取時間，從而增強了下一代提案的臨床和商業性價值。

2025 年的關稅措施將如何改變檢查室和服務供應商的序列供應鏈、採購實務和業務永續營運策略？

美國2025年實施的關稅措施對次世代定序的價值鏈、籌資策略和成本管理實務產生了多方面的影響，但並未改變基因組技術的基本科學價值。關稅增加了進口成本，影響了儀器、試劑和配件的流通，促使各機構重新評估其供應商多元化策略。因此，採購團隊加快了對區域供應商的選擇流程，並尋求簽訂長期合約以穩定價格和供應。同時，製造商和經銷商調整了庫存策略，維持更大的緩衝庫存，並重新評估製造地，以降低關稅相關中斷的風險。

策略性投資以綜合細分分析為指導，該分析將技術類型、產品類型、工作流程階段、最終用戶畫像和應用主導的優先順序連結起來。

關鍵的市場區隔洞察揭示了技術優勢與工作流程需求的交匯點，從而確定了實施和功能優先順序。基於技術，市場涵蓋擴增子定序、基因組定序、RNA定序、標靶定序、全EXOME子定序 (WES) 和全基因組定序 (WGS)，每種技術在深度、廣度和臨床效用方面各有側重，指南平台和檢測方法的選擇。基於產品類型，產品分為耗材和試劑、儀器以及軟體和服務。在耗材和試劑中，重點關注酵素和試劑盒；在儀器中，區分了定序儀和輔助儀器；軟體和服務則細分為資料分析軟體和服務，反映了檢驗分析和受控解讀日益成長的重要性。

影響美洲、歐洲、中東、非洲和亞太地區定序應用、監管協調和基礎設施投資的區域發展趨勢。

區域趨勢持續影響次世代定序技術在各類醫療保健系統、研究網路和商業生態系統中的部署和擴展。在美洲，應用趨勢凸顯了臨床診斷、腫瘤學應用以及由先進的生物資訊學提供者和雲端原生儲存解決方案支援的強大診斷服務市場。北美學術機構和生物技術中心正積極推動方法檢驗和轉化研究，而商業實驗室網路則專注於檢測標準化和高通量工作流程。

競爭生態系統分析揭示了儀器製造商、試劑供應商、分析供應商和服務實驗室如何合作提供整合定定序價值提案。

定序生態系中的競爭格局是儀器製造商、試劑供應商、軟體和分析服務提供者以及服務實驗室相互交織的產物，它們各自追求獨特的價值提案。領先的儀器供應商專注於通量、準確性和整合工作流程解決方案，而試劑和試劑盒供應商則強調可靠性、批間一致性和符合法規要求的文檔，以滿足臨床檢驗需求。軟體和服務供應商則透過檢驗的分析流程、解讀內容和託管服務來減輕檢查室和臨床醫生的分析負擔，從而實現差異化競爭。

為領導者提供實用的策略指導，以協調技術選擇、資料基礎設施、供應鏈彈性和夥伴關係模式，從而負責任地定序規模。

我們為產業領導者提供的切實可行的建議著重於協調技術選擇、營運設計和夥伴關係策略，以最大限度地發揮定序的潛力，同時管控與檢驗、供應鏈和資料管治相關的風險。首先，優先考慮模組化和檢驗的工作流程，以實現分階段擴展。選擇標準化的分析流程、可互通的平台和耗材將縮短臨床部署時間，並簡化監管合規流程。其次，投資於混合資料架構，平衡雲端擴充性和本地管理，以滿足資料主權要求和對延遲敏感的臨床應用情境。第三，制定供應商多元化策略和長期採購協議，以應對關稅和中斷風險，同時維持臨床應用所需的品質和文件標準。

採用三角測量法的調查方法，結合對關鍵相關人員的訪談、檢查室工作流程的基準測試以及與第二手資料的檢驗，對該序列產生了可靠的見解。

本報告的調查方法融合了對主要相關人員的訪談、檢查室工作流程分析以及對二手資訊的嚴格檢驗，從而得出基於證據的結論。關鍵資訊來源包括對儀器工程師、臨床實驗室經理、生物資訊學經理和採購專家的訪談，以了解實際操作中的限制和創新重點。除這些定性研究外，還進行了結構化的工作流程觀察和技術基準評估，重點關注樣本製備、定序和分析各階段的定序準確性、結果獲取時間和整合挑戰。

結論強調，檢驗的工作流程、穩健的營運結構和協作執行對於最大限度地發揮定序技術的臨床和研究價值至關重要。

本執行摘要概述了次世代定序的策略現實。儘管技術進步拓展了其應用範圍和臨床意義，但與工作流程、數據和採購相關的營運複雜性阻礙了其有效實施。相關人員將定序視為一項系統性挑戰，涵蓋儀器選擇、檢驗的耗材、可互通的分析以及穩健的供應鏈。隨著監管機構日益重視檢驗和軟體完整性，可重複的流程和完善的品管系統的重要性進一步凸顯，而與關稅相關的採購趨勢則強調了多元化採購和與供應商建立策略合作關係的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章次世代定序市場：依技術分類

  • 擴增子序列
  • 基因panel定序
  • RNA定序
  • 目標序列
  • 全EXOME定序（WES）
  • 全基因組定序（WGS）

第9章：次世代定序市場：依產品類型分類

  • 耗材和試劑
    • 酵素
    • 成套工具
  • 裝置
    • 相關設備
    • 序列器
  • 軟體服務
    • 數據分析軟體
    • 服務

第10章：次世代定序市場：依工作流程分類

  • 數據分析
    • 結盟
    • 註解
    • 變體調用
  • 資料閘道器
    • 雲端儲存
    • 本地儲存
  • 樣品製備
    • 樣品製備
    • 模板準備
  • 定序

第11章次世代定序市場：依最終用戶分類

  • 學術研究機構
  • 醫療診斷檢測機構
  • 製藥和生物技術公司

第12章次世代定序市場：按應用領域分類

  • 農業基因組學
  • 攜帶者篩檢
  • 表觀基因
  • 法醫學基因組學
  • 遺傳性疾病和罕見疾病
  • 感染疾病
  • 神經基因組學
  • 腫瘤學
  • 藥物基因體學

第13章次世代定序市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章次世代定序市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章次世代定序市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國次世代定序市場

第17章：中國的次世代定序市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • Azenta US, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics
  • GenScript
  • Hamilton Company
  • Illumina, Inc.
  • Invitae Corporation
  • LGC Limited
  • Macrogen Inc.
  • Merck KGaA
  • MGI Tech Co., Ltd.
  • NeoGenomics Laboratories
  • Novogene Co., Ltd.
  • Oxford Nanopore Technologies Plc.
  • Pacific Biosciences of California, Inc.
  • QIAGEN NV
  • Revvity
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4312A385A68A

The Next Generation Sequencing Market was valued at USD 26.69 billion in 2025 and is projected to grow to USD 31.77 billion in 2026, with a CAGR of 24.78%, reaching USD 125.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 26.69 billion
Estimated Year [2026] USD 31.77 billion
Forecast Year [2032] USD 125.78 billion
CAGR (%) 24.78%

A strategic orientation to next generation sequencing that ties technological advances and clinical adoption to operational priorities and stakeholder decision-making

Next generation sequencing (NGS) has transitioned from a niche laboratory technique to a foundational platform shaping biomedical research, diagnostics, and biopharmaceutical innovation. This introduction outlines the technological maturation, broadening clinical applications, and operational challenges that decision-makers must reconcile to harness NGS effectively. Advances in sequencing chemistry, instrument throughput, and bioinformatic toolsets have lowered technical barriers, while real-world deployments in oncology, infectious disease surveillance, and rare disease genetics demonstrate tangible clinical utility. At the same time, organizations face rising expectations for data quality, interoperability, and regulatory compliance as sequencing data increasingly informs patient care and therapeutic development.

Understanding the current landscape requires attention to the interplay between technology evolution and user needs. Laboratories seek reproducible workflows that balance throughput with accuracy, clinicians demand actionable reports that integrate into electronic health record systems, and developers of therapeutics rely on high-fidelity genomic data for biomarker discovery and patient stratification. Consequently, infrastructure considerations such as data storage, scalable compute, and robust analysis pipelines have become as important as instrument selection. As adoption deepens, strategic stakeholders must evaluate not only immediate performance metrics but also long-term operational costs, vendor roadmaps, and ecosystem partnerships.

This summary sets the scene for subsequent sections by emphasizing that NGS is now a systems-level investment. Effective deployment hinges on aligning technical capabilities with workflow requirements and patient-centric outcomes, while adapting to evolving regulatory expectations and global supply chain dynamics.

Converging technological, analytical, and regulatory trends that are redefining sequencing capabilities, validation expectations, and collaborative deployment models

The landscape of next generation sequencing is undergoing transformative shifts driven by multiple converging forces that reshape both capability and adoption. First, instrument innovation continues to prioritize speed, accuracy, and cost-efficiency, enabling new use cases such as rapid infectious disease pathogen identification and real-time oncology monitoring. Second, bioinformatics has shifted from bespoke scripts to increasingly standardized, validated pipelines that incorporate alignment, annotation, and variant calling with reproducible outputs suitable for clinical reporting. These methodological advances reduce variability between laboratories and accelerate time-to-result, which in turn amplifies the clinical and commercial value proposition of NGS.

Concurrently, data management and storage paradigms have evolved; stakeholders increasingly adopt hybrid architectures that combine cloud storage with on-premise compute to reconcile data sovereignty, latency, and security concerns. Integration with electronic health records and clinical decision support tools is becoming more seamless, enabling genomic insights to inform point-of-care decisions. Regulatory frameworks are adapting to this reality, with a stronger focus on analytical and clinical validation, software-as-a-medical-device considerations, and the provenance of reference data sets. Finally, collaboration models are shifting as partnerships between academic centers, diagnostic labs, and biopharma accelerate co-development of assays and companion diagnostics. Together, these shifts create a dynamic environment where technical innovation, validation rigor, and ecosystem partnerships jointly determine the rate and scope of NGS adoption.

How 2025 tariff measures reshaped sequencing supply chains, procurement behaviors, and operational resilience strategies across laboratories and service providers

The introduction of tariffs by the United States in 2025 has exerted a multifaceted influence on next generation sequencing supply chains, procurement strategies, and cost-management practices without altering the underlying scientific value of genomic technologies. Tariff measures affected the flow of instruments, reagents, and ancillary components by increasing landed costs for imported items and prompting organizations to re-evaluate supplier diversification. As a result, procurement teams accelerated vendor qualification processes for regional suppliers and sought longer-term contracts to stabilize pricing and supply commitments. In parallel, manufacturers and distributors adjusted inventory strategies, maintaining higher buffer stocks and revisiting manufacturing footprints to mitigate the risk of tariff-related disruptions.

Operationally, laboratories and service providers adapted by optimizing reagent utilization, consolidating orders, and negotiating bundled service agreements that absorb some tariff-driven cost pressures. For institutions prioritizing clinical continuity, the emphasis shifted toward validated local sourcing and strengthened service-level agreements to ensure instrument uptime. Furthermore, the tariff environment prompted a reassessment of capital allocation timelines: organizations weighed the benefits of acquiring new high-throughput sequencers against incremental import costs and potential delays. At the same time, regulatory compliance and quality control requirements remained non-negotiable, driving investments in workflow efficiencies that preserve analytical performance even as procurement dynamics change. In essence, the cumulative effect of tariffs in 2025 accelerated supply-chain resilience planning and reinforced the importance of integrated procurement and operational strategies to sustain sequencing programs.

Integrated segmentation analysis that aligns technology types, product categories, workflow stages, end-user profiles, and application-driven priorities to guide strategic investment

Key segmentation insights reveal where technological strengths and workflow demands intersect to shape adoption and capability priorities. Based on Technology, the landscape spans Amplicon Sequencing, Gene Panel Sequencing, RNA Sequencing, Targeted Sequencing, Whole Exome Sequencing (WES), and Whole Genome Sequencing (WGS), each offering a distinct balance of depth, breadth, and clinical utility that informs platform and assay selection. Based on Product Type, offerings are organized across Consumables Reagents, Instruments, and Software Services; within Consumables Reagents the focus narrows to Enzymes and Kits, while Instruments distinguish Ancillary Instruments from Sequencers, and Software Services break down into Data Analysis Software and Services, reflecting the rising importance of validated analytics and managed interpretation.

Based on Workflow, critical stages include Data Analysis, Data Storage, Sample Preparation, and Sequencing; Data Analysis further segments into Alignment, Annotation, and Variant Calling, Data Storage differentiates Cloud Storage from On-Premise Storage, and Sample Preparation separates Library Preparation from Template Preparation, underscoring that bottlenecks can occur at multiple touchpoints beyond the sequencer itself. Based on End User, adoption patterns differ among Academic Research Institutes, Healthcare Diagnostic Laboratories, and Pharmaceutical Biotechnology Companies, each of which prioritizes different performance metrics, regulatory rigor, and scale considerations. Based on Application, deployments range across Agrigenomics, Carrier screening, Epigenomics, Forensic Genomics, Genetic & Rare Diseases, Infectious Diseases, Neurogenomics, Oncology, and Pharmacogenomics, demonstrating that application-specific requirements drive assay design, data interpretation needs, and downstream clinical or commercial pathways.

Taken together, these segmentation lenses show that strategic investments should align technology choice with specific workflow pinch points and end-user requirements, while emphasizing interoperable analysis and storage solutions that accommodate diverse applications and validation needs.

Regional deployment dynamics that influence sequencing adoption, regulatory alignment, and infrastructure investments across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics continue to shape how next generation sequencing capabilities roll out and scale across different health systems, research networks, and commercial ecosystems. In the Americas, deployment trends emphasize clinical diagnostics, oncology applications, and a robust diagnostics services market supported by advanced bioinformatics providers and cloud-native storage solutions. North American academic centers and biotech hubs drive method validation and translational research, while commercial lab networks focus on assay standardization and high-throughput workflows.

In Europe, Middle East & Africa, regulatory harmonization, data protection frameworks, and diverse healthcare reimbursement models influence adoption cadence. European research consortia and national public health initiatives frequently collaborate to establish reference standards, while regional manufacturers and service providers respond to varying data sovereignty requirements by offering localized storage and compute options. Emerging hubs in the Middle East and North Africa are investing in sequencing capacity for public health surveillance and precision medicine pilot programs.

Across Asia-Pacific, growth patterns reflect a mix of government-led sequencing initiatives, expansive clinical sequencing adoption in select markets, and strong manufacturing capabilities for instruments and reagents. Several countries prioritize genomics for population health, infectious disease surveillance, and agriculture, prompting significant investments in laboratory infrastructure and workforce training. In each region, the balance of public and private funding, regulatory pathways, and local academic-industry collaborations determines how sequencing technologies are integrated into broader healthcare and research agendas.

Competitive ecosystem analysis revealing how instrument makers, reagent suppliers, analytics vendors, and service laboratories converge to offer integrated sequencing value propositions

Competitive positioning in the sequencing ecosystem reflects a blend of instrument manufacturers, reagent suppliers, software and analytics providers, and service laboratories, each pursuing distinct value propositions. Leading instrument providers concentrate on throughput, accuracy, and integrated workflow solutions, while reagent and kit suppliers emphasize reliability, lot-to-lot consistency, and regulatory-ready documentation to meet clinical validation needs. Software and services vendors differentiate through validated analysis pipelines, interpretive content, and managed services that reduce the interpretive burden on laboratories and clinicians.

Service laboratories and contract research organizations play a complementary role by offering scalable sequencing capacity, assay development partnerships, and decentralized testing models that allow clinical and research customers to access advanced capabilities without immediate capital investment. Strategic partnerships and licensing deals increasingly blur traditional vendor boundaries, as companies combine hardware, consumables, and analytic services into cohesive offerings that accelerate end-to-end validation. In response, purchasers evaluate vendors not only on instrument specifications but also on ecosystem support, data portability, and long-term roadmap commitments that ensure compatibility with evolving clinical standards and bioinformatic requirements.

Practical strategic guidance for leaders to align technology selection, data infrastructure, supply resilience, and partnership models to scale sequencing responsibly

Actionable recommendations for industry leaders focus on aligning technology selection, operational design, and partnership strategies to capture the full potential of sequencing while managing risks related to validation, supply chain, and data governance. First, prioritize modular and validated workflows that allow incremental scaling; selecting platforms and consumables that interoperate with standardized analysis pipelines reduces time-to-clinical-readiness and simplifies regulatory pathways. Second, invest in hybrid data architectures that balance cloud scalability with on-premise control to meet data sovereignty requirements and latency-sensitive clinical use cases. Third, develop supplier diversity strategies and longer-term procurement agreements that address tariff and supply disruption risks while preserving quality and documentation standards required for clinical use.

Additionally, cultivate strategic partnerships that extend beyond transactional procurement: co-development agreements with assay developers, data-sharing partnerships with academic centers, and managed service arrangements with analytics providers accelerate validation and broaden access. Upskilling laboratory staff in bioinformatics and quality systems is essential to maintain analytical rigor as workflows scale, and embedding interpretive expertise into clinical reports will improve clinician confidence and patient outcomes. Finally, regularly assess regulatory trajectories and engage with standards-setting bodies to ensure that internal validation programs and software development practices remain aligned with emerging guidance. These steps together create a resilient, scalable pathway from laboratory innovation to routine clinical impact.

A triangulated research methodology combining primary stakeholder interviews, laboratory workflow benchmarking, and secondary validation to produce robust sequencing insights

The research methodology underpinning this report synthesizes primary stakeholder interviews, laboratory workflow analyses, and rigorous secondary-source validation to ensure evidence-based conclusions. Primary inputs included consultations with instrument engineers, clinical laboratory directors, bioinformatics leaders, and procurement specialists to capture real-world constraints and innovation priorities. These qualitative engagements were complemented by structured workflow observations and technical benchmark assessments that focused on sequencing accuracy, time-to-result, and integration challenges across sample preparation, sequencing, and analysis stages.

Secondary validation incorporated peer-reviewed literature, regulatory guidance documents, and technology white papers to corroborate trends identified in primary research and to contextualize developments in bioinformatics and data management. Where applicable, comparative assessments of analytical pipelines-covering alignment, annotation, and variant calling-were performed to highlight reproducibility considerations and interpretive bottlenecks. The methodology emphasizes triangulation across data sources, transparency in assumptions, and clarity about the limits of inference, ensuring that findings are both actionable and grounded in a robust evidence base. Throughout, the approach maintained strict attention to data integrity, reproducibility, and the practical needs of laboratory and clinical stakeholders.

Concluding synthesis emphasizing that validated workflows, resilient operations, and collaborative execution unlock the full clinical and research value of sequencing technologies

This executive summary synthesizes the strategic realities of next generation sequencing: technological advances have expanded application breadth and clinical relevance, while operational complexities related to workflows, data, and procurement determine effective adoption. Stakeholders must approach sequencing as a systems challenge that spans instrument selection, validated consumables, interoperable analytics, and resilient supply chains. Emerging regulatory emphasis on validation and software integrity increases the premium on reproducible pipelines and documented quality management systems, and tariff-related procurement dynamics highlight the necessity of diversified sourcing and strategic vendor relationships.

Looking forward, the most successful organizations will combine technical excellence with operational foresight-investing in hybrid data infrastructures, workforce upskilling, and collaborative partnerships that accelerate validation and clinical integration. By focusing on validated workflows, robust data governance, and adaptive procurement strategies, leaders can translate sequencing capabilities into measurable research and clinical value. This conclusion underscores that the promise of genomic technologies will be realized not solely through isolated innovations, but through disciplined execution across the full sequencing ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next Generation Sequencing Market, by Technology

  • 8.1. Amplicon Sequencing
  • 8.2. Gene Panel Sequencing
  • 8.3. RNA Sequencing
  • 8.4. Targeted Sequencing
  • 8.5. Whole Exome Sequencing (WES)
  • 8.6. Whole Genome Sequencing (WGS)

9. Next Generation Sequencing Market, by Product Type

  • 9.1. Consumables Reagents
    • 9.1.1. Enzymes
    • 9.1.2. Kits
  • 9.2. Instruments
    • 9.2.1. Ancillary Instruments
    • 9.2.2. Sequencers
  • 9.3. Software Services
    • 9.3.1. Data Analysis Software
    • 9.3.2. Services

10. Next Generation Sequencing Market, by Workflow

  • 10.1. Data Analysis
    • 10.1.1. Alignment
    • 10.1.2. Annotation
    • 10.1.3. Variant Calling
  • 10.2. Data Storage
    • 10.2.1. Cloud Storage
    • 10.2.2. On-Premise Storage
  • 10.3. Sample Preparation
    • 10.3.1. Library Preparation
    • 10.3.2. Template Preparation
  • 10.4. Sequencing

11. Next Generation Sequencing Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Healthcare Diagnostic Laboratories
  • 11.3. Pharmaceutical Biotechnology Companies

12. Next Generation Sequencing Market, by Application

  • 12.1. Agrigenomics
  • 12.2. Carrier screening
  • 12.3. Epigenomics
  • 12.4. Forensic Genomics
  • 12.5. Genetic & Rare Diseases
  • 12.6. Infectious Diseases
  • 12.7. Neurogenomics
  • 12.8. Oncology
  • 12.9. Pharmacogenomics

13. Next Generation Sequencing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Next Generation Sequencing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Next Generation Sequencing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Next Generation Sequencing Market

17. China Next Generation Sequencing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 10x Genomics, Inc.
  • 18.6. Agilent Technologies, Inc.
  • 18.7. Azenta US, Inc.
  • 18.8. Becton, Dickinson and Company
  • 18.9. BGI Genomics Co., Ltd.
  • 18.10. Bio-Rad Laboratories, Inc.
  • 18.11. Danaher Corporation
  • 18.12. Eurofins Scientific SE
  • 18.13. F. Hoffmann-La Roche Ltd.
  • 18.14. Fulgent Genetics
  • 18.15. GenScript
  • 18.16. Hamilton Company
  • 18.17. Illumina, Inc.
  • 18.18. Invitae Corporation
  • 18.19. LGC Limited
  • 18.20. Macrogen Inc.
  • 18.21. Merck KGaA
  • 18.22. MGI Tech Co., Ltd.
  • 18.23. NeoGenomics Laboratories
  • 18.24. Novogene Co., Ltd.
  • 18.25. Oxford Nanopore Technologies Plc.
  • 18.26. Pacific Biosciences of California, Inc.
  • 18.27. QIAGEN N.V.
  • 18.28. Revvity
  • 18.29. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT GENERATION SEQUENCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEXT GENERATION SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 243. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 244. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 246. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 247. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 278. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 279. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 280. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 282. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 283. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 289. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 290. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 291. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 292. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 293. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 294. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 295. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES NEX